Red Rock Home Pharmacy has not been named as a defendant in any of the major lawsuits that Eli Lilly or Novo Nordisk have filed against compounding pharmacies and telehealth companies over compounded GLP-1 weight-loss drugs. The Red Rock Pharmacy lawsuit picture, as it stands in the public record, consists of a single Utah state pharmacy citation issued in 2025 and a broader legal environment that has grown sharply more hostile to 503A compounders like Red Rock since the FDA declared the tirzepatide shortage over.1Bariatric Reports. Red Rock Pharmacy
The Utah Citation on Record
Utah’s Division of Professional Licensing published the only confirmed disciplinary action against the pharmacy in its June 2025 newsletter. “Red Rock Home Pharmacy Springville” received citation number 049100 for a pharmacy violation under license number 10369880-1703, with a fine of $1,050 that the pharmacy paid.2Utah Department of Commerce. Division of Professional Licensing Disciplinary Newsletter The newsletter does not describe the nature of the violation, and no further public records elaborate on it.
No FDA warning letters or federal enforcement actions targeting Red Rock have surfaced in public records.1Bariatric Reports. Red Rock Pharmacy
Why Red Rock Sits in a Risky Legal Position
Red Rock is a 503A state-licensed compounding pharmacy that fills prescriptions for individual patients rather than manufacturing drugs in bulk. It compounds tirzepatide, the active ingredient in Mounjaro and Zepbound, for telehealth platforms including Mochi Health, Fridays, and Zappy Health.1Bariatric Reports. Red Rock Pharmacy Its formulations include glycine as an added ingredient, which the pharmacy uses to argue that its product is not “essentially a copy” of the FDA-approved brand, the legal test that governs what 503A pharmacies can compound.3Red Rock Home Pharmacy. Contact
That argument became critical when the FDA declared the tirzepatide shortage resolved on December 19, 2024. Once the shortage ended, the shortage-based exemption that had allowed pharmacies to compound copies of tirzepatide closed. The FDA set a wind-down deadline of February 18, 2025, for 503A pharmacies to stop compounding tirzepatide under the exemption, and March 19, 2025, for 503B outsourcing facilities. The agency did carve out a narrow exception: it will not pursue a compounder that fills four or fewer prescriptions for a given product per calendar month.4FDA. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize
A federal court challenge to the FDA’s authority, brought by the Outsourcing Facilities Association, failed. In May 2025, a federal judge ruled against the compounders, affirming that the FDA could declare the shortage over and restrict compounding.5Endpoints News. Judge Hands Win to FDA, Lilly in Tirzepatide Shortage Case
Lawsuits Against Other Compounders and a Red Rock Partner
Eli Lilly opened a wave of litigation in April 2025. On the pharmacy side, Lilly sued Strive Pharmacy in the District of Delaware and Empower Pharmacy in the District of New Jersey, alleging deceptive trade practices and false advertising for continuing to compound tirzepatide after the shortage ended.6CNBC. Eli Lilly Sues Strive and Empower Over Compounded Tirzepatide Lilly filed a second action against Empower in the Southern District of Texas in July 2025.7Mondaq. Major Update on GLP-1 Litigation Involving Compounding Pharmacies Red Rock is not a defendant in any of these actions.
On the telehealth side, Lilly sued four companies in the Northern District of California: Mochi Health, Fella Health, Willow Health Services, and Henry Meds, alleging they sold “illegal, unapproved copies” of Mounjaro and Zepbound. Lilly alleged in the Mochi and Fella cases that the companies engaged in the unlawful corporate practice of medicine by exercising control over prescribing decisions and modifying drug formulations.8Pharmaceutical Technology. Eli Lilly Sues Mochi Health and Others for Deceptive Tirzepatide Marketing
The Mochi case matters to Red Rock because Mochi is one of Red Rock’s telehealth partners. Even so, the pharmacy co-defendant Lilly named alongside Mochi was Aequita Pharmacy, not Red Rock. A federal judge dismissed the case without prejudice in October 2025, finding Lilly had not plausibly alleged a concrete injury to establish standing, and gave Lilly leave to amend.9Alliance for Pharmacy Compounding. Eli Lilly v. Mochi Health Corp., Order Granting Motion to Dismiss
Novo Nordisk, maker of semaglutide-based Ozempic and Wegovy, has pursued an even broader campaign. By August 2025, Novo had filed 132 complaints in federal courts across 40 states, and courts had issued 44 permanent injunctions against various defendants.10PR Newswire. Novo Nordisk Expands Legal Action to Protect US Patients From Unsafe Non-FDA-Approved Compounded Semaglutide Red Rock does not appear among the named defendants in the available records.
What Could Still Land on Red Rock
Two exposures remain live even without a case on the docket. First, the FDA has stated it retains authority to take enforcement action against any compounded product it finds to be of substandard quality or unsafe, regardless of shortage status.4FDA. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize Second, the theory driving Lilly’s suits against other compounders is that adding a minor ingredient like glycine is a cosmetic change that does not make a compounded product meaningfully different from the branded drug. That is the same theory Red Rock’s formulation strategy would have to survive if a manufacturer or the FDA turned its attention to the pharmacy. As of the available public record, neither has.